Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy529. [Epub ahead of print] No abstract available.

PMID:
30624616
2.

In Vitro Assessment of Human Natural Killer Cell Migration and Invasion.

Tomin K, Goldfarb RH, Albertsson P.

Methods Mol Biol. 2016;1441:65-74. doi: 10.1007/978-1-4939-3684-7_6.

PMID:
27177657
3.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M.

Ann Oncol. 2014 Mar;25(3):592-8. doi: 10.1093/annonc/mdt543. Epub 2014 Jan 8.

4.

Matrix metalloproteinases in cytotoxic lymphocytes impact on tumour infiltration and immunomodulation.

Edsparr K, Basse PH, Goldfarb RH, Albertsson P.

Cancer Microenviron. 2011 Dec;4(3):351-60. doi: 10.1007/s12307-010-0057-0. Epub 2010 Nov 27.

5.

A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.

Rastelli L, Valentino ML, Minderman MC, Landin J, Malyankar UM, Lescoe MK, Kitson R, Brunson K, Souan L, Forenza S, Goldfarb RH, Rabbani SA.

Int J Oncol. 2011 Aug;39(2):401-8. doi: 10.3892/ijo.2011.1040. Epub 2011 May 11.

PMID:
21567086
6.

Effects of IL-2 on MMP expression in freshly isolated human NK cells and the IL-2-independent NK cell line YT.

Edsparr K, Speetjens FM, Mulder-Stapel A, Goldfarb RH, Basse PH, Lennernäs B, Kuppen PJ, Albertsson P.

J Immunother. 2010 Jun;33(5):475-81. doi: 10.1097/CJI.0b013e3181d372a0.

7.

Human NK cell lines migrate differentially in vitro related to matrix interaction and MMP expression.

Edsparr K, Johansson BR, Goldfarb RH, Basse PH, Nannmark U, Speetjens FM, Kuppen PJ, Lennernäs B, Albertsson P.

Immunol Cell Biol. 2009 Aug-Sep;87(6):489-95. doi: 10.1038/icb.2009.35. Epub 2009 May 12.

PMID:
19434071
8.

Differential locomotion of long- and short-term IL-2-activated murine natural killer cells in a model matrix environment.

Albertsson P, Basse PH, Edsparr K, Kim MH, Goldfarb RH, Kitson RP, Lennernäs B, Nannmark U, Johansson BR.

Scand J Immunol. 2007 Oct;66(4):402-9. Erratum in: Scand J Immunol. 2007 Nov;66(5):601. Golfarb, R H [corrected to Goldfarb, R H].

9.

Differential effects of proteasome inhibitors on cell cycle and apoptotic pathways in human YT and Jurkat cells.

Lu M, Dou QP, Kitson RP, Smith DM, Goldfarb RH.

J Cell Biochem. 2006 Jan 1;97(1):122-34.

PMID:
16173095
10.

Physical association of uPAR with the alphaV integrin on the surface of human NK cells.

Gellert GC, Goldfarb RH, Kitson RP.

Biochem Biophys Res Commun. 2004 Mar 19;315(4):1025-32.

PMID:
14985115
11.

Conformational and enzymatic changes of 20S proteasome of rat natural killer cells induced by mono- and divalent cations.

Reshetnyak YK, Kitson RP, Lu M, Goldfarb RH.

J Struct Biol. 2004 Mar;145(3):263-71.

PMID:
14960377
12.

2B4(CD244)-mediated activation of NK cells reduces metastases of B16F10 melanoma in mice.

Johnson LA, Vaidya SV, Goldfarb RH, Mathew PA.

Anticancer Res. 2003 Sep-Oct;23(5A):3651-5.

PMID:
14666660
13.

NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity.

Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ.

Trends Immunol. 2003 Nov;24(11):603-9. Review.

PMID:
14596885
14.
15.

Bortezomib (millennium pharmaceuticals).

Dou QP, Goldfarb RH.

IDrugs. 2002 Aug;5(8):828-34.

PMID:
12802699
16.

Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases.

Yang Q, Hokland ME, Bryant JL, Zhang Y, Nannmark U, Watkins SC, Goldfarb RH, Herberman RB, Basse PH.

Int J Cancer. 2003 Jul 1;105(4):512-9.

18.

Evidence of inter- and intra-molecular crosslinking of tyrosine residues of calmodulin induced by photo-activation of ruthenium(II).

Andreev OA, Reshetnyak YK, Goldfarb RH.

Photochem Photobiol Sci. 2002 Oct;1(10):834-6.

PMID:
12656487
19.

Different mechanisms of soy isoflavones in cell cycle regulation and inhibition of invasion.

Kim MH, Gutierrez AM, Goldfarb RH.

Anticancer Res. 2002 Nov-Dec;22(6C):3811-7.

PMID:
12552999
20.
21.

Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases.

Datta A, Kitson RP, Xue Y, al-Atrash G, Mazar AP, Jones TR, Goldfarb RH.

In Vivo. 2002 Nov-Dec;16(6):451-7.

PMID:
12494889
22.

Modulation of human NK cell lines by vascular endothelial growth factor and receptor VEGFR-1 (FLT-1).

Chen WS, Kitson RP, Goldfarb RH.

In Vivo. 2002 Nov-Dec;16(6):439-45.

PMID:
12494887
23.

IL-2-mediated upregulation of uPA and uPAR in natural killer cells.

Al-Atrash G, Shetty S, Idell S, Xue Y, Kitson RP, Halady PK, Goldfarb RH.

Biochem Biophys Res Commun. 2002 Mar 22;292(1):184-9.

PMID:
11890690
24.

uPA and uPAR contribute to NK cell invasion through the extracellular matrix.

Al-Atrash G, Kitson RP, Xue Y, Mazar AP, Kim MH, Goldfarb RH.

Anticancer Res. 2001 May-Jun;21(3B):1697-704.

PMID:
11497249
25.

Expression of neutrophil collagenase (MMP-8) in Jurkat T leukemia cells and its role in invasion.

Kim MH, Albertsson P, Xue Y, Nannmark U, Kitson RP, Goldfarb RH.

Anticancer Res. 2001 Jan-Feb;21(1A):45-50.

PMID:
11299777
26.

Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer.

Kuppen PJ, van der Eb MM, Jonges LE, Hagenaars M, Hokland ME, Nannmark U, Goldfarb RH, Basse PH, Fleuren GJ, Hoeben RC, van de Velde CJ.

Histochem Cell Biol. 2001 Jan;115(1):67-72.

PMID:
11219610
27.

Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells.

Nannmark U, Hokland ME, Agger R, Christiansen M, Kjaergaard J, Goldfarb RH, Bagge U, Unger M, Johansson BR, Albertsson PA, Basse PH.

In Vivo. 2000 Sep-Oct;14(5):651-8.

PMID:
11125549
28.

Regulation of IFN-gamma production following 2B4 activation in human NK cells.

Johnson LA, Goldfarb RH, Mathew PA.

In Vivo. 2000 Sep-Oct;14(5):625-9.

PMID:
11125547
29.

Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion.

al-Atrash G, Kitson RP, Xue Y, Goldfarb RH.

In Vivo. 2000 Sep-Oct;14(5):565-70.

PMID:
11125540
30.

Expression of matrix metalloproteinases and their inhibitors by rat NK cells: inhibition of their expression by genistein.

Kim MH, Albertsson P, Xue Y, Kitson RP, Nannmark U, Goldfarb RH.

In Vivo. 2000 Sep-Oct;14(5):557-64.

PMID:
11125539
31.

2B4 stimulation of YT cells induces natural killer cell cytolytic function and invasiveness.

Chuang SS, Kim MH, Johnson LA, Albertsson P, Kitson RP, Nannmark U, Goldfarb RH, Mathew PA.

Immunology. 2000 Jul;100(3):378-83.

32.

A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.

Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP, Rabbani SA.

FASEB J. 2000 Jul;14(10):1400-10.

PMID:
10877833
33.

Blood level of B and CD4+ lymphocytes measured before induction of an experimental tumor in rats predicts tumor progression and survival.

Demetrikopoulos MK, Goldfarb RH, Zhang ZB, Weiss JM.

Cancer Epidemiol Biomarkers Prev. 2000 Jun;9(6):609-17.

34.

Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors.

Kim MH, Kitson RP, Albertsson P, Nannmark U, Basse PH, Kuppen PJ, Hokland ME, Goldfarb RH.

J Immunol. 2000 Jun 1;164(11):5883-9.

35.

Matrix metalloproteinases of human NK cells.

Albertsson P, Kim MH, Jonges LE, Kitson RP, Kuppen PJ, Johansson BR, Nannmark U, Goldfarb RH.

In Vivo. 2000 Jan-Feb;14(1):269-76.

PMID:
10757086
37.

A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin.

Goldfarb RH, Koelemij R, Muirhead KA, Ohlsson-Wilhelm BM, Gray BD, Kuppen PJ, Basse PH, al-Atrash G, Kitson RP.

In Vivo. 2000 Jan-Feb;14(1):101-4.

PMID:
10757065
38.

Enhanced anti-metastatic efficacy of IL-2 activated NK (A-NK) cells with novel benzothiazoles.

Goldfarb RH, Kitson RP, Brunson KW, Yoshino K, Hirota N, Kirii Y, Kotera Y, Inoue Y, Ohashi M.

Anticancer Res. 1999 May-Jun;19(3A):1663-7.

PMID:
10470098
39.

Hepatocyte growth factor (HGF) and receptor (c-met) in normal and malignant astrocytic cells.

Welch WC, Kornblith PL, Michalopoulos GK, Petersen BE, Beedle A, Gollin SM, Goldfarb RH.

Anticancer Res. 1999 May-Jun;19(3A):1635-40.

PMID:
10470094
40.

Evidence for involvement of B lymphocytes in the surveillance of lung metastasis in the rat.

Quan N, Zhang Z, Demetrikopoulos MK, Kitson RP, Chambers WH, Goldfarb RH, Weiss JM.

Cancer Res. 1999 Mar 1;59(5):1080-9.

42.

Flavone acetic acid enhances accumulation of IL-2 activated NK cells within established metastases.

Kitson RP, Ohashi M, Brunson KW, Goldfarb RH.

In Vivo. 1998 Nov-Dec;12(6):593-7.

PMID:
9891222
43.

Cytolytic activities of IL-2 activated NK cells from MMTV/v-Ha-ras transgenic oncomice during tumor progression.

Goldfarb RH, Albertsson P, Nannmark U, Kitson RP.

In Vivo. 1998 Nov-Dec;12(6):589-92.

PMID:
9891221
44.

Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide.

Goldfarb RH, Ohashi M, Brunson KW, Kirii Y, Kotera Y, Basse PH, Kitson RP.

Anticancer Res. 1998 May-Jun;18(3A):1441-6.

PMID:
9673353
45.

Matrix metalloproteinases produced by rat IL-2-activated NK cells.

Kitson RP, Appasamy PM, Nannmark U, Albertsson P, Gabauer MK, Goldfarb RH.

J Immunol. 1998 May 1;160(9):4248-53. Erratum in: J Immunol 1999 Mar 1;162(5):3104.

46.

Retention of adoptively transferred interleukin-2-activated natural killer cells in tumor tissue.

Ribeiro U Jr, Basse PH, Rosenstein M, Safatle-Ribeiro AV, Alhallak S, Goldfarb RH, Posner MC.

Anticancer Res. 1997 Mar-Apr;17(2A):1115-23.

PMID:
9137458
47.

The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions.

McEwen BS, Biron CA, Brunson KW, Bulloch K, Chambers WH, Dhabhar FS, Goldfarb RH, Kitson RP, Miller AH, Spencer RL, Weiss JM.

Brain Res Brain Res Rev. 1997 Feb;23(1-2):79-133. Review. No abstract available.

PMID:
9063588
48.

Immunocytochemical localization of multicatalytic protease complex (proteasome) during generation of murine IL-2-activated natural killer (A-NK) cells.

Nannmark U, Kitson RP, Johansson BR, Rivett AJ, Goldfarb RH.

Eur J Cell Biol. 1996 Dec;71(4):402-8.

PMID:
8980912
50.

Microvessel origin and distribution in pulmonary metastases of B16 melanoma: implication for adoptive immunotherapy.

Nannmark U, Johansson BR, Bryant JL, Unger ML, Hokland ME, Goldfarb RH, Basse PH.

Cancer Res. 1995 Oct 15;55(20):4627-32.

Supplemental Content

Loading ...
Support Center